Gynecologic oncology
-
Gynecologic oncology · Sep 1997
Clinical TrialTopotecan in platinum- and paclitaxel-resistant ovarian cancer.
The purpose of this study was to define the response rate and toxicity of topotecan in patients with ovarian cancer resistant to first-line therapy. ⋯ Topotecan exhibits activity in patients with ovarian cancer resistant to both platinum and paclitaxel. Further study is warranted in less heavily pretreated patients and in combination with other chemotherapeutic agents.